Skip to main content

JCDecaux renews Heathrow advertising contract for 8 years

JCDecaux renews Heathrow advertising contract for 8 years Paris, 30 June 2026 – JCDecaux SE (Euronext Paris: DEC), the number one outdoor advertising company worldwide, announces today the renewal of its contract with Heathrow, the most connected airport in the world, with a record 84.5 million passengers in 2025. The 8-year contract will run from 1 January 2027 and extends a long-standing partnership that spans over 25 years, reinforcing Heathrow as one of the world’s leading premium advertising environments. Heathrow is the UK’s international gateway and for the third consecutive year, ranked as the world’s most connected airport¹, with flights to 230 destinations in over 80 countries¹. As Heathrow celebrates its 80th birthday, the partnership will support the next phase of growth in Heathrow’s media offering, while enhancing the experience...

Continue reading

BUREAU VERITAS – In line with the LEAP | 28 portfolio rotation strategy, Bureau Veritas signs an agreement to sell its Oil & Petrochemicals and Coal Testing and Inspection business

PRESS RELEASECourbevoie – June 30, 2026 In line with the LEAP | 28 portfolio rotation strategy, Bureau Veritas signs an agreement to sell its Oil & Petrochemicals and Coal Testing and Inspection business Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces that it has entered exclusive negotiations with Triton Partners regarding the sale of its Oil & Petrochemicals and Coal testing and inspection business. This strategic divestment is in full alignment with the Group’s LEAP | 28 strategy. The proposed transaction would include the Oil & Petrochemicals and Coal testing and inspection activities. In 2025, this business generated approximately EUR 450 million in revenue operating a global network across multiple countries, with a significant footprint of operational sites and employees....

Continue reading

FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

The filing application is based on improvements seen across key efficacy endpoints from the global phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double vision) in active TED Enspryng (satralizumab) has the potential to become the first at-home subcutaneous disease-modifying standard of care for TED TED is an autoimmune disease affecting approximately 155 out of every 100,000 people that can lead to facial disfigurement and vision threatening complications if left untreatedBasel, 30 June 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental Biologics License Application (sBLA) for Enspryng® (satralizumab) for the treatment of thyroid eye disease (TED). The filing acceptance...

Continue reading

GXO and Co-op Extend Transport Partnership with New Five year Agreement

GXO and Co-op Extend Transport Partnership with New Five year AgreementSupporting deliveries to more than 1,000 stores with shared values to create lasting social value in communities nationwideGXO and Co-op Extend Transport Partnership with New Five year AgreementNew agreement extends GXO and Co op’s transport operations partnership to over 20 yearsNew agreement extends GXO and Co‑op’s transport operations partnership to over 20 years Supporting deliveries to more than 1,000 stores with shared values to create lasting social value in communities nationwideLONDON, June 30, 2026 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, has announced a five-year transport contract expansion with Co‑op, one of the world’s largest consumer co-operatives, advancing...

Continue reading

The National Proton Therapy Center of Portugal will be equipped with two IBA Proteus®ONE solutions

Louvain-La-Neuve, Belgium, June 30, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today the entering into effect of a contract with Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto), for the installation of two Proteus®ONE1 compact proton therapy solutions at the IPO-Porto facilities in Porto, Portugal. The two Proteus®ONE systems will be the first proton therapy systems in the country and will serve as the National Proton Therapy Center of Portugal. Signed last April, the contract enters into effect after a statutory thorough review of the selection process by the Portuguese Tribunal de Contas (Court of Auditors). The contract between IPO-Porto and IBA also includes a...

Continue reading

Mowi enters into a Share Purchase Agreement to divest its 9k GWT salmon farming operations in Canada East

(Bergen, 30 June 2026). Mowi has today entered into a Share Purchase Agreement to divest its 9k GWT salmon farming operations in Canada East to Cooke Inc. for CAD 225 million on a debt-free basis in order to further improve Mowi’s farming portfolio and focus even more on core farming geographies.   Canada East will be booked as held for sale until closing pending competition approval and confirmatory due diligence by Cooke Inc. Closing is expected to take place sometime in the second half of 2026 and is subject to customary closing conditions. The transaction will reduce Mowi’s volume guidance for 2026 from 605k GWT to 600k GWT. In connection with the transaction, Mowi will take a write-down of approx. CAD 140 million. For further information, please contact:Kristian Ellingsen, CFO, Mowi, +47 905 14 275Kim Galtung Døsvig, IR Officer &...

Continue reading

Digital Realty Prices Secondary Offering of Common Stock by Blackstone

AUSTIN, Texas, June 30, 2026 (GLOBE NEWSWIRE) — Digital Realty (NYSE: DLR), the largest global provider of cloud- and carrier-neutral data center, colocation and interconnection solutions, announced today the pricing of an underwritten registered public offering of 12,310,249 shares of its common stock by affiliates of Blackstone Inc. (collectively, “Blackstone”) at a public offering price of $185.00 per share. The shares of common stock being sold in this offering will be issued to Blackstone upon the closing of the acquisition by the company of Blackstone’s interests in the Digital Carver Dulles 9 and Digital Carver Brickyard joint ventures (the “Blackstone Acquisition”), which is expected to occur on June 30, 2026. Each share of non-voting common stock will automatically convert into one share of the company’s...

Continue reading

Questerre Preferred Shares commence trading on Euronext Growth

THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS CALGARY, Alberta, June 30, 2026 (GLOBE NEWSWIRE) — Questerre Energy Corporation (“Questerre” or the “Company”) announced today that the Company’s Series 2 Preferred Shares (the “Preferred Shares”) have been admitted to trading on Euronext Growth Oslo under the ticker “QGAS”. The Preferred Shares commence trading today. There are approximately 45.2 million Preferred Shares outstanding following the 10:1 consolidation approved by shareholders on June 23, 2026. The Preferred Shares track the economic performance and value of the Company’s Quebec assets, including its significant natural gas discovery in the Quebec Utica shale, among the largest undeveloped natural...

Continue reading

Sigenergy Breaks Ground on Phase II Intelligent Energy Center and Joint Venture Production Facility in Nantong

Sigenergy broke ground on Phase II of its Nantong Intelligent Energy Center, alongside a new joint venture production facility.Sigenergy broke ground on Phase II of its Nantong Intelligent Energy Center, alongside a new joint venture production facility.NANTONG, China, June 29, 2026 (GLOBE NEWSWIRE) — Since phase I was put into full -load production early this year, Sigenergy has officially broken ground on June 29th on Phase II of its Nantong Intelligent Energy Center and a new joint venture production facility for energy storage structural components. Located in the Nantong Sutong Science and Technology Industrial Park, the expansion marks a major milestone in scaling the company’s AI-driven smart manufacturing and global supply chain. Following the successful launch of Phase I early this year, the completion of Phase...

Continue reading

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a price of $20.00 per share, with expected gross proceeds to Nuvectis of $100 million. Nuvectis has also granted the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about July 1, 2026, subject to satisfaction of customary closing conditions. Cantor is acting as sole book runner for the offering. H.C....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.